[{"address1": "Cedar Brook Corporate Center", "address2": "4-B Cedar Brook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 495 2200", "fax": "609 495 2202", "website": "https://palatin.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl  Spana Ph.D.", "age": 61, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1074250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Wills CPA, MST", "age": 66, "title": "CFO, COO, Executive VP, Treasurer & Secretary", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1098144, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Burns  McClellan", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen A. Slusher Esq.", "title": "Chief Legal Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Raizman M.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James E. Hattersley", "age": 63, "title": "Senior Vice President of Business Development", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Dodd Ph.D.", "title": "Senior Vice President of Preclinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Jordan", "title": "Senior Vice President of Program Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.8799, "open": 0.8731, "dayLow": 0.8301, "dayHigh": 0.8955, "regularMarketPreviousClose": 0.8799, "regularMarketOpen": 0.8731, "regularMarketDayLow": 0.8301, "regularMarketDayHigh": 0.8955, "beta": 0.994, "forwardPE": 0.4681383, "volume": 209746, "regularMarketVolume": 209746, "averageVolume": 236696, "averageVolume10days": 278110, "averageDailyVolume10Day": 278110, "bidSize": 1200, "askSize": 1100, "marketCap": 17204372, "fiftyTwoWeekLow": 0.68, "fiftyTwoWeekHigh": 5.65, "priceToSalesTrailing12Months": 3.831632, "fiftyDayAverage": 1.2934, "twoHundredDayAverage": 2.08605, "currency": "USD", "enterpriseValue": 8267324, "floatShares": 17546826, "sharesOutstanding": 19548200, "sharesShort": 1349648, "sharesShortPriorMonth": 1371450, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.069, "heldPercentInsiders": 0.03502, "heldPercentInstitutions": 0.14876, "shortRatio": 3.65, "shortPercentOfFloat": 0.0706, "bookValue": -0.006, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -29736112, "trailingEps": -2.02, "forwardEps": 1.88, "lastSplitFactor": "1:10", "lastSplitDate": 1285545600, "enterpriseToRevenue": 1.841, "enterpriseToEbitda": -0.276, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PTN", "underlyingSymbol": "PTN", "shortName": "Palatin Technologies, Inc.", "longName": "Palatin Technologies, Inc.", "firstTradeDateEpochUtc": 876922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef61cf2b-791e-37b7-b04c-9ccb76a1630d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8801, "targetHighPrice": 17.0, "targetLowPrice": 6.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 9527396, "totalCashPerShare": 0.487, "ebitda": -29938890, "totalDebt": 590338, "quickRatio": 0.987, "currentRatio": 1.012, "totalRevenue": 4490090, "revenuePerShare": 0.306, "returnOnAssets": -1.3195701, "freeCashflow": -17108668, "operatingCashflow": -31461440, "revenueGrowth": -0.801, "operatingMargins": -23.787529, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-14"}]